Literature DB >> 2213917

Tardive dyskinesia successfully treated with alprazolam.

H W Jordan1, B C Williams.   

Abstract

Tardive dyskinesia is a disorder secondary to prolonged treatment (from 18 months to 3 years) with antipsychotic agents, affecting approximately 15% to 20% of patients. Tardive dyskinesia is characterized by difficulty controlling involuntary movements of the small muscle groups, producing tic-like reactions, muscle rigidity, and difficulty maintaining muscle tone. It is a chronic and unrelenting disorder which may be permanent if not successfully treated. The mechanism of action is thought to be secondary to dopamine hypersensitivity resulting from prolonged deprivation of dopamine on the part of dopamine-sensitive receptors. Theoretically, these receptors have been deprived of the neurotransmitter by chronic treatment with antipsychotic drugs, which are recognized as dopamine-blocking agents. We present a case in which alprazolam was successfully used in treating tardive dyskinesia.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2213917      PMCID: PMC2626990     

Source DB:  PubMed          Journal:  J Natl Med Assoc        ISSN: 0027-9684            Impact factor:   1.798


  3 in total

Review 1.  GABA system: clinical research and treatment of tardive dyskinesia.

Authors:  G K Thaker; T A Hare; C A Tamminga
Journal:  Mod Probl Pharmacopsychiatry       Date:  1983

2.  Clonazepam and tardive dyskinesia.

Authors:  T R Barnes; T Kidger
Journal:  Am J Psychiatry       Date:  1981-08       Impact factor: 18.112

3.  Diazepam-induced changes in tardive dyskinesia: suggestions for a new conceptual model.

Authors:  M M Singh; R E Becker; R K Pitman; H A Nasrallah; H Lal; R L Dufresne; S S Weber; M McCalley-Whitters
Journal:  Biol Psychiatry       Date:  1982-06       Impact factor: 13.382

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.